Hervé Tilly/X
Nov 15, 2024, 16:49
Long-Term Outcomes of Mini-CHOP Plus Anti-CD20 in Elderly DLBCL Patients
Ajay Major, Assistant Professor of Medicine at the University of Colorado School of Medicine, shared a post on X:
“Mini-CHOP in age 80+ from LYSA trials by Hervé Tilly at ASH24:
– 269 patients, mFU 12 years.
– mPFS 2.4 years, mOS 4.1 years, 5-years PFS 38%, OS 44%.
– most common COD: lymphoma (36%), TRM 5%.
– TRM during treatment after institution of pre phase. Great long-term data in older DLBCL.”
Ajay Major is an Assistant Professor of Medicine at the University of Colorado School of Medicine, specializing in lymphoma and CLL/SLL. He is the Founder and President of Pager Publications, as well as the Founder and Editor-in-Chief of in-House. Additionally, he serves as a Reviewer for the Bellevue Literary Review.
More posts featuring Ajay Major.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 15, 2024, 16:49
Nov 15, 2024, 16:48
Nov 15, 2024, 16:44
Nov 15, 2024, 16:42
Nov 15, 2024, 16:41
Nov 15, 2024, 16:34
Nov 15, 2024, 16:14